Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Azenta reports resilient Q4 performance and outlines growth strategies

Azenta's Q4 2024 earnings call highlighted strong financial results, strategic decisions, and future growth initiatives amidst market challenges and uncertainties.
The company's focus on core businesses, competitive strengths in Sample Management Solutions and Multiomics, and commitment to shareholder value enhancement position it for success in 2025.
While facing revenue declines and market-related queries, Azenta's proactive approach to portfolio optimization, operational efficiency, and capital allocation sets the stage for sustainable growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service.

Azenta Announces CEO Succession Plan

BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024.

Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024

BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2024 earnings which ended on March 31, 2024, on Wednesday, May 8, 2024, after the market closes.

Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast

BURLINGTON, Mass. , April 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

Azenta Publishes its 2023 Environmental, Social, & Governance (ESG) Report

BURLINGTON, Mass. , April 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 23rd Annual Needham Virtual Healthcare Conference, on Monday, April 8, 2024, which includes a presentation beginning at 12:45 pm ET.

Azenta to Participate in the 23rd Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass. , March 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET.

Azenta to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

Azenta, Inc. (AZTA) Q1 2024 Earnings Call Transcript

BURLINGTON, Mass. , Feb. 7, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2023.

Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023

argenx

Axsome Therapeutics

Inari Medical

Vericel

While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.

5 medical stocks growing earnings by triple digits

BURLINGTON, Mass. , Feb. 2, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of the BioArc™ Ultra (the "Ultra"), a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance for large-scale sample management with the potential to forever change the landscape of biorepositories.

Azenta Launches the BioArc™ Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management

BURLINGTON, Mass. , Jan. 25, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2024 earnings which ended on December 31, 2023, on Wednesday, February 7, 2024, after the market closes.

Azenta Announces Fiscal 2024 First Quarter Earnings Conference Call and Webcast

BURLINGTON, Mass. , Jan. 11, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Thursday, March 14, 2024 in New York City.

Azenta to Host Investor Day on March 14, 2024

BURLINGTON, Mass. , Jan. 9, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 26th Annual Needham Growth Conference in New York, NY, on Thursday, January 18, 2024, which includes a presentation beginning at 10:15 am ET.

Azenta to Participate in the 26th Annual Needham Growth Conference

BURLINGTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will present at the 42nd Annual J.P.

Azenta to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

BURLINGTON, Mass. , Nov. 21, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in 1x1 meetings at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL, on Wednesday, November 29, 2023.

Azenta to Participate in the 6th Annual Evercore ISI HealthCONx Conference

monday.com

Star Bulk Carriers

In a somewhat quiet earnings lineup this week, several stocks stand out after posting strong quarterly results on Monday.

3 Stocks to Watch After Impressive Earnings Beats

Azenta, Inc. (NASDAQ:AZTA ) Q4 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Sara Silverman - Head of IR Steve Schwartz - President and CEO Herman Cueto - CFO Conference Call Participants David Saxon - Needham Jacob Johnson - Stephens Andrew Cooper - Raymond James Paul Knight - KeyBanc Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Operator Thank you, and welcome to the Azenta Q4 2023 Financial Results.

Azenta, Inc. (AZTA) Q4 2023 Earnings Call Transcript

Shares of Azenta Inc. AZTA, +0.59% jumped 11.9% after hours on Monday after the life-sciences company reported fourth-quarter results that beat expectations and announced plans to buy back an extra $500 million in stock in fiscal 2024. The company — whose products and services help researchers store, handle and process chemical and biological samples — reported net income of $3.4 million, or 6 cents a share, compared with a loss of $20.8 million, or 28 cents a share, in the same quarter last year.

Azenta shares jump on Q4 results, buyback plans

Q4'23 reported revenue growth of 25% year over year and 2% on an organic basis FY'23 reported revenue growth of 20% and down 1% on an organic basis Q4'23 generated positive free cash flow for the second consecutive quarter Fiscal 2024 organic revenue growth expected to be 5-8% Committing to an additional $500 million in share repurchases in Fiscal 2024 BURLINGTON, Mass. , Nov. 13, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

Azenta Reports Fourth Quarter and Full Year Fiscal 2023 Results, Ended September 30, 2023

Nominates Didier Hirsch and Martin Madaus for election to the Board of Directors Upon the election of Messrs. Hirsch and Madaus, seven of the Board of Directors' ten members will have been added since 2018 Separately, Azenta today announced strong 2023 fourth quarter and full year fiscal 2023 earnings results, with commitment to additional $500 million in share repurchases in Fiscal 2024  BURLINGTON, Mass.

Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation

BURLINGTON, Mass. , Nov. 13, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that B Medical Systems S.

Azenta Announces Agreement Between B Medical and The Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo for a Significant National Universal Health Project

BURLINGTON, Mass., Nov. 10, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on Wednesday, November 15, 2023, and Thursday, November 16, 2023.

Azenta to Participate in the Stephens Annual Investment Conference

Azenta, Inc., formerly Brooks Automation, sold its semiconductor business and subsequently became a pure play life science business. Azenta's shares have declined significantly and its valuation is still supported by net cash holdings. However, Azenta is not profitable, making it difficult to be optimistic about its shares.

Azenta: Life Science Play Suffers A Bad Diagnosis

BURLINGTON, Mass. , Nov. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2023 earnings which ended on September 30, 2023 on Monday, November 13, 2023 after the market closes.

Azenta Announces Fiscal 2023 Fourth Quarter and Full Year Earnings Conference Call and Webcast

BURLINGTON, Mass. , Oct. 19, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting GENEWIZ Week November 6-10, 2023.

News for Azenta Stock (AZTA)